Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

237 ARTÍCULOS , VIENDO DEL 226 AL 237

Therapeutic plasma exchange for a case of refractory opsoclonus myoclonus ataxia syndrome

Greensher JE, Louie J, Fish JD.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26819. Epub 2017 Sep 19.

Mutations in AIFM1 cause an X-linked childhood cerebellar ataxia partially responsive to riboflavin

Heimer G, Eyal E, Zhu X, Ruzzo EK, Marek-Yagel D, Sagiv D, Anikster Y, Reznik-Wolf H, Pras E, Oz Levi D, Lancet D, Ben-Zeev B, Nissenkorn A.

Eur J Paediatr Neurol. 2018 Jan;22(1):93-101. doi: 10.1016/j.ejpn.2017.09.004. Epub 2017 Sep 15.

Kinsbourne syndrome associated with cryptococcosis infection

Cavalcante-Filho JRM, Alves-Filho FWP, Araújo GB, Braga-Neto P, Ribeiro EML.

Parkinsonism Relat Disord. 2018 Feb;47:86-87. doi: 10.1016/j.parkreldis.2017.11.005. Epub 2017 Nov 10.

Functional Impairments in a Patient with Morvan Syndrome: A Case Presentation

Tow S, Carozza D, Barker K.

PM R. 2018 Jul;10(7):766-769. doi: 10.1016/j.pmrj.2017.10.014. Epub 2017 Dec 6.

HIV-associated opsoclonus-myoclonus-ataxia syndrome: early infection, immune reconstitution syndrome or secondary to other diseases? Case report and literature review

Guedes BF, Vieira Filho MAA, Listik C, Carra RB, Pereira CB, Silva ERD, Gomes HR, Vidal JE.

J Neurovirol. 2018 Feb;24(1):123-127. doi: 10.1007/s13365-017-0603-3. Epub 2017 Dec 14.

More than ataxia - Movement disorders in ataxia-telangiectasia

Teive HAG, Camargo CHF, Munhoz RP.

Parkinsonism Relat Disord. 2018 Jan;46:3-8. doi: 10.1016/j.parkreldis.2017.12.009. Epub 2017 Dec 12.

Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia

Kannoth S, Nambiar V, Gopinath S, Anandakuttan A, Mathai A, Rajan PK.

Neurol Sci. 2018 Mar;39(3):455-460. doi: 10.1007/s10072-017-3222-0. Epub 2017 Dec 20.

Principles and approaches to the treatment of immune-mediated movement disorders

Mohammad SS, Dale RC.

Eur J Paediatr Neurol. 2018 Mar;22(2):292-300. doi: 10.1016/j.ejpn.2017.11.010. Epub 2017 Dec 19.

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL.

Lancet Child Adolesc Health. 2018 Jan;2(1):25-34. doi: 10.1016/S2352-4642(17)30130-X. Epub 2017 Nov 3.

Autoimmune and paraneoplastic movement disorders: An update

Baizabal-Carvallo JF, Jankovic J.

J Neurol Sci. 2018 Feb 15;385:175-184. doi: 10.1016/j.jns.2017.12.035. Epub 2017 Dec 30.

Understanding heterogeneity in conduct disorder: A review of psychophysiological studies

Fanti KA.

Neurosci Biobehav Rev. 2018 Aug;91:4-20. doi: 10.1016/j.neubiorev.2016.09.022. Epub 2016 Sep 28.

Histological characterisation of visceral changes in a patient with type 2 Gaucher disease treated with enzyme replacement therapy

Tezuka Y, Fukuda M, Watanabe S, Nakano T, Okamoto K, Kuzume K, Yano Y, Eguchi M, Ishimae M, Ishii E, Miyazaki T.

Blood Cells Mol Dis. 2018 Feb;68:194-199. doi: 10.1016/j.bcmd.2016.11.006. Epub 2016 Nov 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias